HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval95% confidence

Prescription Drug User Fee Amendments

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to PROD DEVELOPMENT; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.

Supporting Context

Therapeutic area
Neurology · Antiepileptic
Sub-indication
General

Related signal: FDA Grants Approval for Lacosamide ANDA217596

Source

View source document

Related Signal

Open signal — FDA Grants Approval for Lacosamide ANDA217596
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.